Research Reports on Investment Opportunities丨Galaxy Securities: Maintains "Recommended" rating for Jointown Pharmaceutical Group, the first pharmaceutical REITs has been approved.

Gelonghui, December 27 | Galaxy Securities Research Reports pointed out that Jointown Pharmaceutical Group (600998.SH) announced the approval from the China Securities Regulatory Commission for its public REITs concerning pharmaceutical warehousing and logistics infrastructure. As the only approved public REITs asset symbol in the pharmaceutical industry, it is rare. Its core business is based on traditional distribution, and it actively promotes the implementation of the 'three new and two transformations' Global Strategy to guide the rapid development of innovative businesses such as CSO and New Retail. Profit contributions from the REITs issuance are not considered for now, and the company's net income attributable to the parent is expected to be 22.20/2 for 2024-2026.

Gelonghui FinanceDec 27, 2024 16:44 · Ratings

Express News | GF SEC resumes coverage on Jointown Pharmaceutical Group, rating it as a buy with a Target Price of 6.48 yuan.

BreakingsDec 26, 2024 21:21

Jointown Pharmaceutical Group (600998): The first medical REITs has been approved, optimizing asset structure.

Event: On December 25, 2024, Jointown Pharmaceutical Group Co., Ltd. announced that its public offering of REITs for pharmaceutical storage and logistics infrastructure has been approved by the China Securities Regulatory Commission. The first national REITs for pharmaceutical storage facilities has officially been obtained.

Silver Galaxy SecuritiesDec 26, 2024 19:07

Research Reports on Investment Opportunities | GF SEC: Initiates a "Buy" rating for Jointown Pharmaceutical Group with a Target Price of 6.48 yuan.

Gelonghui December 26 | GF SEC's research report points out that Jointown Pharmaceutical Group (600998.SH) is a leader in the external pharmaceutical commerce sector, with a compound annual growth rate of over 15% in both revenue and profit over the past 10 years. Public REITs have been approved, and the PRE-REITs project is progressing smoothly, which will enable a synergistic win-win outcome between Jointown and public REITs on a 'dual listing' platform. Based on comparable company valuations, coupled with Jointown's status as a leader in external pharmaceutical commerce, the company is expected to accelerate its development pace following the future issuance of REITs, potentially entering a new phase of light asset development. It is believed that a PE valuation of 15 times for 2024 is appropriate for the company, aligning with its reasonable value.

Gelonghui FinanceDec 26, 2024 16:33 · Ratings

Jointown Pharmaceutical Group (600998): Public offering REITs approved, the leading player in the out-of-hospital commercial sector is expected to enter a new phase of light asset development.

Core viewpoint: The leading company in external pharmaceutical commerce has seen a compound annual growth rate of both revenue and profit of over 15% in the past 10 years. Jointown Pharmaceutical Group is the largest private pharmaceutical commerce enterprise in China, with a Business layout covering the entire Industry Chain, and has now completed "full-category procurement, full-channel coverage and full".

GF SECDec 26, 2024 16:12

Express News | Three public REITs products were approved on the same day.

BreakingsDec 25, 2024 21:55